
Sagimet Biosciences Inc.
Sagimet Biosciences Inc. (SGMT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
sgmt · stock forecast · 7 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$8.00
+22.5% upside
Low
$8.00
Median: $8 · Last Close: $6.53
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $6.36 | ↓ 2.61% |
1-day model range: $6.31–$6.41. Peak: $6.41 (-2.61%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | -50.0% |
| 2028 | $2 | -62.5% |
| 2029 | $2 | -67.2% |
| 2030 | $2 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SGMT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-19 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-05-04 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-04-29 | Guggenheim | Maintains | Buy→Buy |
| 2026-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-14 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-10-02 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-06-06 | Jones Trading | Maintains | Buy→Buy |
| 2025-03-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Sagimet Biosciences Inc. (SGMT) stock. Of the recent 29 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover SGMT.
Analyst Recommendation Trends
SGMT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.5% YoY
Revenue Next Year
$8M
↑ 6673.9% YoY
EPS This Year
$-1.20
EPS Next Year
$-1.25
↑ 4.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast SGMT EPS of $-1.20 for the current fiscal year, based on estimates from 7 analysts. The SGMT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SGMT stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SGMT price target is $8.00 (+22.5% upside), with an analyst consensus of Buy.
The SGMT short-term stock prediction for tomorrow is $6.36 (-2.61%). The SGMT stock price prediction for 2027 estimates an average of $3. The SGMT stock prediction for 2030 projects a range of $2–$2.
Sagimet Biosciences Inc. trades on NASDAQ under the ticker SGMT. The SGMT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
SGMT forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month SGMT price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +22.5% potential upside from the current price of $6.53.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.